Medical Advocates
NNRTIs
  Main Page

 New and Noteworthy               Pediatric Data
General Reports                      Adolescent/Adult Data
 Pharmacokinetics
Diagnostics/Monitoring
 Viral Dynamics
Hypersusceptibility
Adherence
 Resistance Data
 Adverse Events
Drug/Drug Interactions
Efficacy
Virological Failure		  
Drugs Main Page HIV Main Page Main New/Newsworthy Home Page    

Last Update:  December 08, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
October 2014
 
General Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
 Müller R, Mulani I, Basson AE, et al 
Bioorg Med Chem Lett. 2014 Aug 13
 Abstract

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.
Simpson KN, Hanson KA, Harding G,  et al
 AIDS Care. 2014 Apr;26(4):466-75.
 Abstract

Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S, Ravet S, Camus C,  et al 
J Med Virol. 2014 Mar;86(3):394-403.
Abstract

Lack of Effect of Doxycycline on Trough Concentrations of Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients.
 Abgrall S, Le Bel J, Lele N,  et al
HIV Clin Trials. 2013 Nov-Dec;14(6):313-8
 Abstract

Design of novel leads: ligand based computational modeling studies on non-nucleoside reverse transcriptase inhibitors (NNRTIs) of HIV-1
Jain Pancholi N, Gupta S, Sapre N, Sapre NS.
 Mol Biosyst. 2013 Dec 2.
Abstract

Clinical Relevance of the Interaction when Switching Non-Nucleoside Reverse Transcriptase Inhibitors in Patients Infected with HIV.
Dailly E, Allavena C, Deslandes G,  et al 
Curr Clin Pharmacol. 2013 Nov 11..
Abstract

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.
 Simpson KN, Hanson KA, Harding G, et alA
IDS Care. 2013 Oct 10.
Abstract

Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.
Simpson KN, Hanson KA, Harding G, et al
 Health Qual Life Outcomes. 2013 Oct 3;11(1):164..
 Abstract

Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS).
De Clercq E.
 Adv Pharmacol. 2013;67:317-58.
Abstract

Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
Allavena C, Rodallec A, Sécher S, et al
J Med Virol. 2013 Jul 16. .
Abstract

Rational Design of Potent Non-Nucleoside Inhibitors of HIV Reverse Transcriptase.
Peat AJ, Chong PY, Garrido DM, et al
J Med Chem. 2012 Nov 8.
Abstract

Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs.
 Rawal RK, Murugesan V, Katti SB.
 Curr Med Chem. 2012 Sep 10
Abstract

In search of a treatment for HIV – current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Reynolds C, de Koning CB, Pelly SC,  et al
Chem Soc Rev. 2012 May 22.
Abstract

The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study.
Cotte L, Bénet T, Billioud C, Miailhes P, et a
J Hepatol. 2010 Sep 19.
Abstract

Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G, Coluccia A, Silvestri R.
 Antivir Chem Chemother. 2010 Aug 11;20(6):213-
 Abstract 

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP.
Antiviral Res. 2009 Sep 22.
Abstract 

Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART: Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
Cuzin L, Allavena C, Morlat P, Dellamonica P.
AIDS Rev. 2008 Oct-Dec;10(4):205-11.
 Abstract 
 
FULL-TEXT ARTICLE
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.
Parienti JJ, Das-Douglas M, Massari V, et al
PLoS ONE. 2008 Jul 30;3(7):e2783.
 Paper
 
Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: The development pipeline and recent clinical data.
Sweeney ZK, Klumpp K. 
Curr Opin Drug Discov Devel. 2008 Jul;11(4):458-70
Abstract 
 
The Current Status of the NNRTI Family of Antiretrovirals Used in the HAART Regime Against
HIV Infection.
Martins S, Ramos MJ, Fernandes PA.et al 
Curr Med Chem. 2008;15(11):1083-95.
Abstract 

Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N, Tachedjian G. 
Virus Res. 2008 Mar 25
Abstract 
 
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C, Hendra H, Vogel M, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract 
 
Active Methamphetamine Use is Associated with Transmitted Drug Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors in Individuals with HIV Infection of Unknown Duration
Cachay ER, Moini N, Kosakovsky Pond SL, et al
Open AIDS J. 2007;1:5-10
 Abstract 
 
Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
 Shikuma CM, Yang Y, Glesby MJ, et al
J Acquir Immune Defic Syndr. 2007 Jan 22;
Abstract 
 
A WEEK-IN-REVIEW FEATURED REPORT
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
Molto J, Blanco A, Miranda C, Miranda J, et al 
Br J Clin Pharmacol. 2007 Jan 12;
 Abstract
 
The Level of Reverse Transcriptase (RT) in Human Immunodeficiency Virus Type 1 Particles Affects Susceptibility to Nonnucleoside RT Inhibitors but Not to Lamivudine.
Ambrose Z, Julias JG, Boyer PL, et al  
J Virol. 2006 Mar;80(5):2578-81.
 Abstract
 
Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Thomas-Geevarghese A, Raghavan S, Minolfo R, et al   
Am J Clin Nutr. 2005 Jul;82(1):146-54.
 Abstract
 
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.
Portsmouth S, Imami N, Pires A, et al.
HIV Med. 2004 Jan; 5(1): 26-9.
Abstract
 
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational
studies.
Wood E, Hogg RS, Heath KV, et al A
AIDS. 2003 Dec 5;17(18):2629-2634
 Abstract

Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Rizzo RC, Udier-Blagovic M, Wang DP
J Med Chem 2002 Jul 4;45(14):2970-87
 Abstract
 

  
     Conference Reports, Abstracts, and Posters
 
 
CONFERENCE POSTER
The impact of NNRTIs compared to PIs on the development of cancer:
is there a difference?
N. Crum-Cianflone, K. Huppler Hullsiek, A. Ganesan, et al 
(5th IAS Conference)
PDF Poster     Abstract

NNRTIs-based HAART in clinical practice. A retrospective study
 BM Celesia, L Nigro, S Mavilla,et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract

Does gender or ethnicity influence treatment outcomes in antiretroviral naive patients commencing non-nucleoside reverse transcriptase inhibitor (NNRTI) based HAART?
 NT Annan, S Mandalia, M Bower, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Gender difference in immunological response to non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimen in HIV-1 infected Indian patients
 K Patel, A Patel, J Patel, et al
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
Pharmacokinetics Data
 
     Journal Papers, Abstracts, and Commentaries
 
  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.
Usach I, Melis V, Peris JE
 J Int AIDS Soc. 2013 Sep 4;16(1):1-14.
Abstract

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside
resistance phenotype
Van Laethem K, Witvrouw M, Pannecouque C, et al.
AIDS 2001 Mar 30;15(5):553-61
Abstract
Diagnostics/Monitoring
 
     Journal Papers, Abstracts, and Commentaries
 
  An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Oct 31;
Abstract
Drug/Drug Interactions
Database of ARV Drug Interactions    
  Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and Raltegravir-Based Antiretroviral Regimens (March).
Patel N, Abdelsayed S, Veve M, Miller CD
 Ann Pharmacother. 2011 Mar 8.
 Abstract
Efficacy Data
 

     Journal Papers, Abstracts, and Commentaries

 
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial.
Lennox JL, Landovitz RJ, Ribaudo HJ,  et al 
Ann Intern Med. 2014 Oct 7;161(7):461-71.
 Abstract

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Gay CL, Mayo AJ, Mfalila CK,  et al 
AIDS. 2011 Apr 24;25(7):941-949.
Abstract

Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS, Quinn JB.
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
Abstract
 
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, et al
Lancet. 2006 Dec 16;368(9553):2107-9.
Abstract
 
Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R, Fu R, Huffman LH, Korthuis PT.
Lancet. 2006 Oct 28;368(9546):1503-15.
Abstract
 
The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.
Arribas JR.
J Antimicrob Chemother. 2004 Jul 28
Abstract

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients.
von Giesen HJ, Koller H, Theisen A, Arendt G.
Acquir Immune Defic Syndr 2002 Apr1;29(4):363-7
 Abstract

   
  Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing  regimens using observational databases.
Ghani AC, Henley WE, Donnelly CA et al.
AIDS 2001 Jun 15;15(9):1133-42  
Abstract

     Conference Reports, Abstracts, and Posters

 
POSTER
Analysis of N348I mutation in the connection domain of HIV-1 reverse transcriptase and impact in the efficacy of zidovudine and non-nucleoside reverse transcriptase inhibitors
J.C. Mendez, J.D. Yao
 (7th IAS Conference)
Poster      Abstract
Viral Dynamics Data
 

     Journal Papers, Abstracts, and Commentaries

 
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or
both in INITIO: open-label randomised trial.INITIO Trial
International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, et al 
Lancet. 2006 Jul 22;368(9532):287-98
Abstract
 
Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as
a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced
HIV-Positive Individuals.
 Winston A, Amin J, Hales G, et al 
AIDS Res Hum Retroviruses. 2006 Apr;22(4):338-41.
 Abstract
 
Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group.
Mocroft A, Ledergerber B, Viard JP, et  al. 
J Infect Dis. 2004 Dec 1;190(11):1947-1956.
 Abstract
 
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
 Abstract

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral
suppression.
Negredo E, Cruz L, Paredes R, et al.
Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract
Hypersusceptibility
 
  Journal Papers, Abstracts, and Commentaries
 
Drug resistance. NNRTI hypersusceptibility.
Delgado J, Shulman N.  
AIDS Read. 2005 Jan;15(1):28-30, 32-4. R
 Abstract

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility:
a prospective cohort analysis.
Haubrich RH, Kemper CA, Hellmann NS, et al
AIDS 2002 Oct 18;16(15):F33-40
 Abstract

  
Adherence
 
     Journal Papers, Abstracts, and Commentaries
 
  Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Taneja C, Juday T, Gertzog L et al 
Expert Opin Pharmacother. 2012 Sep 13
 Abstract

Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients.
Maggiolo F, Airoldi M, Kleinloog HD, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
 Abstract 

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic
outcomes.
Nachega JB, Hislop M, Dowdy DW, et al 
Ann Intern Med. 2007 Apr 17;146(8):564-73
Abstract 
Resistance
 

     Journal Papers, Abstracts, and Commentaries

 
Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S, Ravet S, Camus C,et al
 J Med Virol. 2013 Nov 19.
 Abstract 

Roles of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors.
Xu HT, Colby-Germinario SP, Huang W,  et al
Antimicrob Agents Chemother. 2013 Sep 3
 Abstract 

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
 Anta L, Blanco JL, Llibre JM, García F,et al
J Antimicrob Chemother. 2013 Apr 29
 Abstract 

The prevalence and economic burden of 1st-generation NNRTI resistance.
Snedecor S, Khachatryan A, Nedrow K,  et al
J Int AIDS Soc. 2012 Nov 11;15(6):18204
 Abstract 

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations,
adherence, and the risk of virologic failure.
Li JZ, Paredes R, Ribaudo HJ, et al
 AIDS. 2012 Jan 14;26(2):185-192
 Abstract 

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*).
Cozzi-Lepri A, Paredes R, Phillips A, et al
HIV Med. 2011 Aug 17
 Abstract 

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis.
Li JZ, Paredes R, Ribaudo HJ, et al
JAMA. 2011 Apr 6;305(13):1327-35.
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M,  et al 
AIDS Res Hum Retroviruses. 2010 May 10
 Abstract

A Novel Molecular Mechanism of Dual Resistance to NRTIs and NNRTIs.
Nikolenko GN, Delviks-Frankenberry KA, Pathak VK. 
J Virol. 2010 Mar 10.
 Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the
Second-Generation Agents
Adams J, Patel N, Mankaryous N, Tadros M, Miller CD.
Ann Pharmacother. 2009 Dec 8.
 Abstract

Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation
Nonnucleoside Reverse Transcriptase Inhibitors.
Varghese V, Shahriar R, Rhee SY, et al
J Acquir Immune Defic Syndr. 2009 Sep
Abstract

HIV-1 Resistance to First- and Second-Generation Non-nucleoside Reverse Transcriptase Inhibitors.
Ghosn J, Chaix ML, Delaugerre C.
AIDS Rev. 2009 Jul-Sep;11(3):165-73
 Abstract

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
 Tambuyzer L, Azijn H, Rimsky LT, et al
Antivir Ther. 2009;14(1):103-9.
 Abstract
 
The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z, Herman BD, Sheen CW, 
J Virol. 2009 Feb 4
 Abstract
 
Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J, Stammers DK
Virus Res. 2008 Feb 28
Abstract
 
Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients.
Maggiolo F, Airoldi M, Kleinloog HD, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
 Abstract
 
Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor-Resistant HIV-1 among Recently Infected Infants Born in the United States.
Persaud D, Palumbo P, Ziemniak C, et al
J Infect Dis. 2007 May 15;195(10):1402-10
Abstract
 
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
 Palmer S, Boltz V, Maldarelli F,et al 
AIDS. 2006 Mar 21;20(5):701-710. R
 Abstract
 
Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: A French nationwide study.
Masquelier B, Costagliola D, Schmuck A,0.  
J Med Virol. 2005 Aug;76(4):441-6.
Abstract
 
Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays.
Shulman NS, Delgado J, Bosch RJ, et al 
Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81
 Abstract

The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Ciancio BC, Trotta MP, Lorenzini P, et al  
Antivir Ther. 2003 Dec;8(6):611-6.
Abstract

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits  recycling efavirenz after nevirapine failure.
Antinori A, Zaccarelli M, Cingolani A, et al.
AIDS Res Hum Retroviruses 2002 Aug 10;18(12):835-8
 Abstract
 

  
  Prevalence of nonnucleoside reverse transcriptase inhibitor(NNRTI) resistance-associated mutations and polymorphisms inNNRTI-naive HIV-infected patients.
Clevenbergh P, Cua E, Dam E, et al.
HIV Clin Trials 2002 Jan-Feb;3(1):36-44
 Abstract
 
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and
modifications after stopping NNRTI therapy.
Quiros-Roldan E, Airoldi M, Moretti F,  et al.  
Clin Lab Anal 2002;16(2):76-8
 Abstract   
 
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase nhibitors.
Auwerx J, North TW, Preston BD,
Mol Pharmacol 2002 Feb;61(2):400-6
 Abstract 
 
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.        
Delaugerre C, Rohban R, Simon A et al.
J Med Virol 2001 Nov;65(3):445-8 
Abstract 
 
Structural mechanisms of drug resistance for mutations at codons181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside
inhibitors.
Ren J, Nichols C, Bird L, Chamberlain P, et al.
J Mol Biol 2001 Sep 28;312(4):795-805
 Abstract
 
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
Torti C, Pozniak A, Nelson M, et al.
J Antimicrob Chemother 2001 Jul;48(1):113-6
Abstract 
 
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-  experienced HIV-infected patients: impact on virological  response to efavirenz-
based therapy.
Shulman N, Zolopa AR, Passaro D, et al.
AIDS 2001 Jun 15;15(9):1125-32
Abstract 
 
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Deeks SG.
J Acquir Immune Defic Syndr 2001 Mar 1;26 Suppl 1:S25-33
Abstract 
 
FULL-TEXT PAPER
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication  fitness in cell culture.
Archer RH, Dykes C, Gerondelis P, Lloyd A,
Virol 2000 Sep;74(18):8390-401
Paper
 
 
     Conference Reports, Abstracts, and Posters
 

POSTER
First Low Detectable Viremia (FDV) and Resistance-Associated Mutation under NonNucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen
JM Chapplain, A Ruffault , N Kerriguy, et al
(1st European Drug Resist. Wkshp)
 Poster

POSTER
 Mutations at reverse transcriptase codon 103: phenotypic resistance to non-nucleoside reverse transcriptase inhibitor and clinical correlates
PR Harrigan, et al.
(12 International  Drug Resistance Workshop)
Poster
Adverse Events
 

     Journal Papers, Abstracts, and Commentaries  

 
FULL-TEXT PDF ARTICLE
 Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.
 Frentz D, Van de Vijver DA, Abecasis AB,  et al
BMC Infect Dis. 2014 Jul 21;14(1):407
Paper

Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
Simpson K, Chen SY, Wu A,  et al
HIV Med. 2014 Mar 18.
Abstract

Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC, Li HJ, Dai LL,  et al
Chin Med J (Engl). 2010 Dec;123(24):3587-90.
Abstract

Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity.
Blas-Garcia A, Esplugues JV, Apostolova N. et al
 Curr Med Chem. 2011 Apr 26.
Abstract

Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen.
Conesa-Botella A, Florence E, Lynen L, et al 
AIDS Res Ther. 2010 Nov 23;7(1)
Abstract

Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
Haddow LJ, Wood CW, Ainsworth JG  .
Int J STD AIDS. 2007 May;18(5):343-6.
Abstract
 
Lipodystrophies related to antiretroviral treatment of HIV infection
Capeau J, Caron M, Vigouroux C,et al
Med Sci (Paris). 2006 May;22(5):531-536.
Abstract

 
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase
inhibitor-based regimen. 
Martinez V, Marcelin AG, Morini JP, et al
 AIDS. 2005 Jul 1;19(10):1065-1069.
Abstract
 
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N, Dieterich DT.
Semin Liver Dis. 2003 May;23(2):173-82.
Abstract

NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F, Torralba M.
J HIV Ther 2002 Nov;7(Suppl 2):S3-S9
Abstract

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
Palmon R, Koo BC, Shoultz DA, Dieterich DT.
J Acquir Immune Defic Syndr 2002 Apr1;29(4):340-5
 Abstract
 

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders  in human immunodeficiency  virus-infected patients.
Chene G, Angelini E, Cotte L, et al.
Clin Infect Dis 2002 Mar 1;34(5):649-57
Abstract   
 
Virological Failure
 
     Journal Papers, Abstracts, and Commentaries
 
  Response to Antiretroviral Treatment After Failure of NNRTI plus NRTIs-Based Therapy.
Data from the ARCA Collaborative Group.
Seminari E, De Silvestri A, Meini G,  et al
Curr HIV Res. 2012 May 10.
Abstract

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES,
AIDS. 2012 Jan 14;26(2):185-192
Abstract
Pediatric Data
 

     Journal Papers, Abstracts, and Commentaries

 
Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Treating HIV-Infected Children.
Penazzato M, Giaquinto C. 
Drugs. 2011 Nov 12;71(16):2131-49
 Abstract  

Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy.
Puthanakit T, Kerr SJ, Ananworanich J,   et al 
Pediatr Infect Dis J. 2009 Apr 28.
 Abstract  

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR, Green H, Khoo S, et al
Clin Infect Dis. 2008 May 15;46(10):1601-8
 Abstract  

The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.
 Maddocks S, Dwyer D.  
Paediatr Drugs 2001;3(9):681-702
 Abstract  
 
     Conference Reports, Abstracts, and Posters
 
  POSTER
Impact of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral
therapy (ART)
on weight and Height of Antiretroviral-naïve HIV-infected children
L. Aurpibul, T. Puthanakit, S. Taecharoenkul, V. Sirisanthana
(5th IAS Conference)
PDF Poster     Abstract
Adolescent/Adult Data
 

     Journal Papers, Abstracts, and Commentaries

 
Effect of Non-Nucleoside Reverse Transcriptase Inhibitors on Cytokine, Chemokine, and Immunoglobulin Profiles in Serum and Genital Secretions of HIV-Infected Women.
Sachdeva RK, Wanchu A, Bagga R,  et al
 J Interferon Cytokine Res. 2010 Feb 28
 Abstract

Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort   of HIV-infected women.
Gandhi M, Benet LZ, Bacchetti P, et al 
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):482-91
 Abstract

Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptaseinhibitor-based antiretroviral therapy.
Sullivan AK, Burton CT, Nelson MR
Scand J Immunol. 2003 Jun;57(6):600-7.
Abstract

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.
Raffi F, Bonnet B, Ferre V, et al.  
Clin Infect Dis 2000 Nov;31(5):1274-8
Abstract  

Drugs Main Page HIV Main Page Main New/Newsworthy Home Page  

Non-Nucleoside Reverse Transcriptase Inhibitors